Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.92 Insider Own2.30% Shs Outstand345.47M Perf Week1.60%
Market Cap3.73B Forward P/E2.29 EPS next Y4.72 Insider Trans-70.01% Shs Float332.18M Perf Month-33.19%
Income-2409.00M PEG- EPS next Q0.91 Inst Own66.80% Short Float14.16% Perf Quarter-24.25%
Sales9.67B P/S0.39 EPS this Y-714.90% Inst Trans20.37% Short Ratio2.54 Perf Half Y-61.00%
Book/sh9.01 P/B1.20 EPS next Y21.85% ROA-5.20% Target Price17.53 Perf Year-62.54%
Cash/sh1.57 P/C6.89 EPS next 5Y12.95% ROE-52.70% 52W Range10.35 - 38.50 Perf YTD-25.55%
Dividend- P/FCF2.08 EPS past 5Y12.66% ROI-1.60% 52W High-71.92% Beta-0.14
Dividend %- Quick Ratio1.10 Sales past 5Y31.90% Gross Margin73.00% 52W Low4.44% ATR0.68
Employees21500 Current Ratio1.40 Sales Q/Q-12.20% Oper. Margin-5.90% RSI (14)34.35 Volatility3.59% 5.91%
OptionableYes Debt/Eq9.47 EPS Q/Q-41.70% Profit Margin-24.90% Rel Volume0.48 Prev Close10.75
ShortableYes LT Debt/Eq9.47 EarningsFeb 28 BMO Payout- Avg Volume18.53M Price10.81
Recom3.00 SMA20-10.37% SMA50-21.58% SMA200-45.45% Volume8,919,595 Change0.56%
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Mar-27-17 08:52PM  Valeant Ex-CEO Pearson Sues Drugmaker Over Withheld Shares
06:42PM  Former Valeant CEO sues company over unmade compensation -WSJ Reuters
06:02PM  [$$] Valeant Former CEO Sues Company Over Unmade Payments at The Wall Street Journal
12:43PM  TransDigm: The End is Nigh? at Barrons.com
09:30AM  Drug Manufacturers Continue to be Plagued by Pricing Concerns: Today's Research Reports on Valeant Pharmaceuticals and Mylan Accesswire
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
Mar-25-17 02:01PM  Can You Guess Which Drugmaker Has the Most Debt? (Hint: It's Not Valeant) at Motley Fool
Mar-24-17 05:45PM  Johnson & Johnson's CEO Believes Trump Is Missing the Point on Drug-Price Reform at Motley Fool
01:52PM  Francis Chou Comments on Valeant
01:48PM  Chou Opportunity Fund 4th Quarter Message to Shareholders
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
09:05AM  Valeants Diversified Products Revenue May Drop in 2017
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 09:15PM  The 'Dogs' of Wall Street: Here's a Look at Some of the Worst Performing Stocks of the Year
02:47PM  A Safer Way to Play Valeant and Community Health at Barrons.com
11:05AM  'Female Viagra' founder: GOP health bill would hurt the 'sexual revolution'
10:49AM  Valeant CEO Compensation Revealed, Shares Climb
10:35AM  Siliq May be a Strong Growth Driver for Valeant in 2017
10:26AM  Bill Ackman Is Back at the Sohn Investment Conference This Year at The Wall Street Journal
10:16AM  Valeant: Room to Move? at Barrons.com
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
07:36AM  Valeants Dermatology Business Felt Pricing Pressure in 2016
Mar-22-17 06:33PM  Valeant Closes Down Slightly After Completing Refi
01:48PM  Valeant Rearranges Deck Chairs
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
09:48AM  Valeant's IBS-D Drug Could See Competition with FDA Changes at Investopedia
09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
09:06AM  Xifaxan Expected to Witness Robust Growth in 2017
07:37AM  Headwinds Seen by Valeant Pharmaceuticals in 2016
Mar-21-17 04:51PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation
04:32PM  Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA
04:30PM  Valeant Completes Refinancing Transactions PR Newswire
04:30PM  Valeant Completes Refinancing Transactions CNW Group
04:04PM  Rite Aid, Valeant Drop into Tuesdays 52-Week Low Club
01:23PM  Valeant Completes Bond Tender Offer at The Wall Street Journal
10:54AM  Jazz Sleep Disorder Drug Positive in Phase III Studies
10:37AM  Valeants Net Profit Margins Expected to Narrow in 2017
10:02AM  Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'
09:07AM  Valeant Pharmaceuticals Expects Lower Revenue in 2017
08:55AM  [$$] Options Traders Bet on More Big Moves in Valeant at The Wall Street Journal
07:37AM  Analysts Recommendations for Valeant Pharmaceuticals in 2017
07:00AM  Biotech Bull Making a Comeback
05:00AM  With Ackman Out, Valeant Confronts Rocky Road to Revival
12:12AM  Traders Turn to Valeant Options to Bet on Big Moves at The Wall Street Journal
Mar-20-17 09:45PM  Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 PR Newswire
09:45PM  Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 CNW Group
09:34PM  [$$] Traders Bet on More Big Moves in Valeant at The Wall Street Journal
05:00PM  Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod PR Newswire
05:00PM  Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod CNW Group
04:10PM  Valeant - It's Not a Game of Chess Part II
02:20PM  3 lessons from Bill Ackman's $4B trading loss in Valeant
12:25PM  Valeant: What's the Prescription? at Barrons.com
10:21AM  Traders Turn to Valeant Options to Bet on Big Moves at The Wall Street Journal
09:40AM  Another Smart Hedge Fund Manager Is About to Be Duped By Valeant's Value Trap at Motley Fool
01:00AM  Chipotle, Herbalife, Sears: Doug Kass' Views
12:07AM  William Ackmans Valeant Loss Is Short-Sellers Gain at The Wall Street Journal
Mar-19-17 01:40PM  Stocks Decline to Their 3-Year Lows
Mar-18-17 12:56PM  Hedge Fund Hairball at Forbes
12:20PM  Why Are So Many Employees Selling Stock Options - And Is That Really a Good Idea?
Mar-17-17 05:48PM  Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase
04:24PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:02PM  William Ackman's Valeant Loss Is Short-Sellers' Gain at The Wall Street Journal
03:07PM  Did Ackman Make the Right Decision to Sell Valeant?
01:09PM  Ackman's Valeant Holdings Lost Pershing $7.7 Million a Day at Investopedia
01:02PM  ValueAct bet another $32 million on Valeant as stock hits 8-year low at MarketWatch
12:29PM  Valeant: Dude, Where'd My Gains Go? at Barrons.com
12:27PM  Stocks Fluctuate as Amgen Leads Another Health Care Selloff
10:56AM  Apple, Caterpillar, Valeant, and More: Why These Five Stocks Are in the Spotlight at Insider Monkey
10:37AM  This Key Measure Shows the S&P Could Be Headed for a 5% Pullback
10:04AM  Stocks to Watch: Adobe, Tiffany, Valeant at The Wall Street Journal
09:20AM  Tiffany shines on beat, Valeant is getting some love, Adobe does it again
09:14AM  Valeant Pharmaceuticals: Some Activist Investors Still Like It at Barrons.com
08:27AM  Stock Futures Mixed as Crude Rises, G-20 Summit Kicks Off at TheStreet
08:18AM  Pres Trump to meet with Angela Merkel after calling her policies 'insane'
07:52AM  Early movers: TIF, ADBE, CAT, VRX, NFLX, C, AAPL, KKR, GOOS & more at CNBC
06:00AM  The Contrarian: Analyst Crapshoot on Valeant at Investopedia
05:16AM  Valeant: Don't Get Stuck In The Revolving Door at Investopedia
Mar-16-17 05:59PM  Valeant shares pop 4% after activist investor ValueAct ups stake at CNBC
05:05PM  Valeant Shares Skyrocket After Hours on ValueAct Buy
04:56PM  Here's how much Valeant short sellers have been killing it ever since Bill Ackman got in the stock
03:36PM  Valeant: Yes, Ackman's a Loser. But How Much Did Short Sellers Make? at Barrons.com
01:22PM  Valeant: It's Not a Game of Chess- Part I
12:35PM  Court allows Allergan shareholders to go after Ackman, Valeant as a class at bizjournals.com
06:30AM  Ackman's Investors Won't Get Their Yachts
Mar-15-17 05:02PM  Why I Won't Be Bottom-Fishing Shares in Valeant at Motley Fool
11:35AM  What Ackmans exit means for Valeant at MarketWatch
10:32AM  Bill Ackman Playing Herbalife Like a Rookie, Too
10:21AM  Why Valeant, Oclaro, Time Warner, and More Are in the Spotlight at Insider Monkey
10:14AM  Valeant: No, This is Not a Good Time to Buy at Barrons.com
10:10AM  Company News for March 15, 2017
09:45AM  Is Valeant Finished Now That Ackman Is Out of the Picture?
09:30AM  Today's Feature on Companies from the Biotech Sector: Adeptus Health and Valeant Pharmaceuticals Accesswire
09:22AM  After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead
08:55AM  Stifel Out With 4 Contrarian Stocks to Buy With Big Upside Potential
07:58AM  Valeant: Traders Vs. Portfolio Managers
07:00AM  Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses PR Newswire
07:00AM  Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses CNW Group
06:32AM  Apple, Facebook and Tesla: Off the Charts
06:24AM  Nucor: Cramer's Top Takeaways
06:23AM  Prologis: Cramer's Top Takeaways
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM